Брахитерапия с использованием постоянных источников при раке предстательной железы

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2004 году. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3 прил 1).

2. Ragde H., Korb L.J., Elgamal A.A. et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135—41.

3. Fuks Z., Leibel S.A., Wallner K.E. et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991;21:537—47.

4. Brandeis J.M., Litwin M.S., Burnison C.M. et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000;163:851—7.

5. Holm H.H. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol 1997;13:431—7.

6. Wallner K., Chiu-Tsao S.T., Roy J. et al. An improved method for computerized tomography-planned transperineal 125iodine prostate implants. J Urol 1991;146:90—5.

7. Nag S., Bice W., DeWyngaert K. et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221—30.

8. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol 1991;137(Suppl):113—8.

9. Stone N.N., Stock R.G. Prostate brachytherapy in patients with prostate volumesS50 cm(3): dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000;46:1199—204.

10. Crook J., McLean M., Catton C. et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453—60.

11. Cha C.M., Potters L., Ashley R. et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;45:391—5.

12. Lee L.N., Stock R.G., Stone N.N. Role of hormonal therapy in the management of intermediateto high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52:444—52.

13. Dubois D.F., Prestidge B.R., Hotchkiss L.A. et al. Intraobserver and interobserver variability of MR imagingand CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology 1998;207:785—9.

14. Han B.H., Demel K.C., Wallner K. et al. Patient reported complications after prostate brachytherapy. J Urol 2001;166:953—7.

15. Desai J., Stock R.G., Stone N.N. et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998;6:135—41.

16. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160:1379—82.

17. Crook J., McLean M., Catton C. et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453—60.

18. Merrick G.S., Butler W.M., Dorsey A.T. et al. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:667—74.

19. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:119—24.

20. Snyder K.M., Stock R.G., Hong S.M. et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335—41.

21. Zelefsky M.J., Cowen D., Fuks Z. et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999;85:2460—8.

22. Merrick G.S., Wallner K., Butler W.M. et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001;50:597—604.

23. Stock R.G., Kao J., Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001;165:436—9.

24. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035—41.

25. Kattan M.W., Potters L., Blasko J.C. et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393—9.

26. Stock R.G., Stone N.N., Tabert A. et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41:101—8.

27. Potters L., Cao Y., Calugaru E. et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:605—14.

28. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465—71.

29. Blasko J.C., Grimm P.D., Sylsvester J.E. et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273—8.

30. Whittington R., Broderick G.A., Arger P. et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44:1107—10.

31. Stone N.N., Stock R.G. Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer. Mol Urol 1999;3:239—44.

32. Nag S. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations. Semin Urol Oncol 2000;18:133—6.